ストックスクリーナーアプリを入手
27.04
1.92%
-0.53
アフターアワーズ：
27.03
-0.010
-0.04%
前日終値:
$27.57
開ける：
$27.73
24時間の取引高:
29.06M
Relative Volume:
0.66
時価総額：
$153.81B
収益：
$62.58B
当期純損益:
$7.79B
株価収益率:
19.95
EPS:
1.3551
ネットキャッシュフロー:
$9.08B
1週間 パフォーマンス:
+0.26%
1か月 パフォーマンス:
-2.21%
6か月 パフォーマンス:
+13.80%
1年 パフォーマンス:
+8.12%
1日の値動き範囲:
$27.02
$27.77
1週間の範囲:
$26.44
$27.80
52週間の値動き範囲:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.04 | 156.83B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
878.24 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer (NYSE:PFE) Trading Down 2%Here's Why - MarketBeat
Pfizer Options Spot-On: On March 27th, 99,614 Contracts Were Traded, With 2.42 Million Open Interest - Moomoo
Pfizer: Why Wall Street Habitually Overestimates Target Price (NYSE:PFE) - Seeking Alpha
Spotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection - Pfizer
Vanguard reports 0 Pfizer shares after realignment (NYSE: PFE) - Stock Titan
Why Pfizer Remains A Strong Buy In 2026 (NYSE:PFE) - Seeking Alpha
Jim Cramer Broke Down 5 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Is Pfizer’s Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE? - simplywall.st
Local Anesthesia Drugs Market Is Going to Boom Rapidly | Septodont, Pfizer Inc., Pacira BioSciences, Inc. - openPR.com
Pfizer Inc (PFE): Our Calculation of Intrinsic Value - The Acquirer's Multiple
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data - Insider Monkey
Why the Market Dipped But Pfizer (PFE) Gained Today - Yahoo Finance
Pfizer Options Spot-On: On March 26th, 100.37K Contracts Were Traded, With 2.39 Million Open Interest - Moomoo
Could Buying Eli Lilly Today Set You Up for Life? - The Motley Fool
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer - investing.com
Income Investors Face a Hard Truth About Pfizer’s Payout Safety - Yahoo Finance
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate - simplywall.st
After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data - NAI500
Lyme disease vaccine 70 percent effective: Pfizer - MSN
Pfizer Inc. stock steady as Guggenheim hikes target to $36 amid Lyme vaccine Phase 3 success - ad-hoc-news.de
Is Pfizer Stock a Buy After This Win? - The Globe and Mail
Pfizer (NYSE:PFE) Shares Up 1.2% After Analyst Upgrade - MarketBeat
Pfizer Options Spot-On: On March 25th, 76,121 Contracts Were Traded, With 2.36 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Pfizer/Metsera wins Matter of the Year at GCR Awards - Global Competition Review
Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA® - Yahoo Finance
A Lyme Disease Vaccine May Be on the Way - inc.com
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade (NYSE:PFE) - Seeking Alpha
Pfizer's trispecific antibody shows promise against eczema - BioXconomy
Pensionfund Sabic Makes New $1.86 Million Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer's Comirnaty Vaccine Variant-Adapted for 2025/2026 Season Gains Global Launch Momentum Amid Ob - AD HOC NEWS
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer - news.financial
Pfizer: Time To Buy The Turnaround (NYSE:PFE) - Seeking Alpha
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts - BioSpace
Pfizer Inc. stock steady amid Guggenheim target hike to $36 and fresh Lyme vaccine data as analysts - AD HOC NEWS
Doctors say Pfizer's Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown - abcnews.com
Doctors say Pfizer’s Lyme disease vaccine trial results ‘encouraging’ after more than 70% efficacy shown - Rural Radio Network
Pfizer Options Spot-On: On March 24th, 87,620 Contracts Were Traded, With 2.32 Million Open Interest - Moomoo
Pfizer Inc. stock navigates mini-tender warning and Guggenheim target hike amid pipeline optimism - AD HOC NEWS
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - Yahoo Finance
Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook - TradingView
Press Release: Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call With Analysts - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Pfizer Inc. stock faces mini-tender warning amid Guggenheim target hike and valuation debate - AD HOC NEWS
Pfizer (NYSE:PFE) Price Target Raised to $36.00 - MarketBeat
Guggenheim Raises Pfizer (PFE) Price Target to $36 with a Buy Ra - GuruFocus
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Guggenheim raises Pfizer stock price target on drug trial outlook - investing.com
Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC - MarketBeat
Park Place Capital Corp Trims Position in Pfizer Inc. $PFE - MarketBeat
PFIZER INC : Jefferies keeps its Buy rating - marketscreener.com
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
2.74%
大文字化:
|
ボリューム (24 時間):